Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights Health Tech: Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and the delivery of...


http://dlvr.it/TB0D1r

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology